Maria C Cid

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4660023/publications.pdf

Version: 2024-02-01

166 papers	20,167 citations	18482 62 h-index	10734 138 g-index
175 all docs	175 docs citations	175 times ranked	12578 citing authors

#	Article	IF	Citations
1	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	1.9	7
2	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306.	5.6	78
3	Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. European Journal of Internal Medicine, 2022, 95, 61-66.	2.2	12
4	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology, 2022, 61, 2915-2922.	1.9	24
5	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmunity Reviews, 2022, 21, 103034.	5.8	8
6	Blocking GM-CSF receptor Î± with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2022, 81, 524-536.	0.9	26
7	Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.9	49
8	Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome. Frontiers in Immunology, 2022, 13, 840974.	4.8	3
9	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.8	3
10	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. Annals of the Rheumatic Diseases, 2022, 81, 1290-1300.	0.9	20
11	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	6.5	23
12	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia, 2021, 35, 2635-2649.	7.2	32
13	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatology, The, 2021, 3, e328-e336.	3.9	52
14	An 80-year-old man with headache, orbital pain and elevated ESR: challenges in the diagnosis of a patient with suspected giant cell arteritis. Rheumatology, 2021, 60, iii12-iii14.	1.9	1
15	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Scientific Reports, 2021, 11, 14404.	3.3	8
16	Risks and benefits of tocilizumab monotherapy in giant cell arteritis. Lancet Rheumatology, The, 2021, 3, e606-e607.	3.9	0
17	The COVID-19 pandemic and ANCA-associated vasculitis â€“ reports from the EUVAS meeting and EUVAS education forum. Autoimmunity Reviews, 2021, 20, 102986.	5.8	25
18	Large-vessel vasculitis. Nature Reviews Disease Primers, 2021, 7, 93.	30.5	74

#	Article	IF	Citations
19	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology, 2020, 59, 1574-1580.	1.9	47
20	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.9	667
21	PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Advances, 2020, 4, 4217-4231.	5.2	23
22	B55Î±/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling. Circulation Research, 2020, 127, 707-723.	4.5	24
23	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
24	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
25	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. Rheumatology, 2020, 59, iii17-iii27.	1.9	9
26	A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. Modern Rheumatology Case Reports, 2019, 3, 130-133.	0.7	0
27	Usefulness of imaging techniques in the management of giant cell arteritis. Medicina ClÃnica (English) Tj ETQq1 1 0.784314 rgBT /Ov	0.2	0
28	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
29	185.â€ƒGENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	1.9	0
30	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2019, 143, 2170-2177.	2.9	82
31	Glucocorticoid Dosages and Acuteâ€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis and Rheumatology, 2019, 71, 1329-1338.	5.6	74
32	Utilidad de las tÃ©cnicas de imagen en la valoraciÃ³n de la arteritis de cÃ©lulas gigantes. Medicina ClÃnica, 2019, 152, 495-501.	0.6	3
33	SP0073â€…DIAGNOSIS OF GASTROINTESTINAL VASCULITIS. , 2019, , .		0
34	FRI0487â€…UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2
35	THU0008â€…GM-CSF PATHWAY SIGNATURE IDENTIFIED IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		8
36	FRI0466â€…RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0

#	Article	IF	Citations
37	FRI0284â€…RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
38	THU0286â€…MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
39	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases, 2019, 78, 399-405.	0.9	165
40	HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 151-152.	0.8	1
41	Biological treatments in giant cell arteritis & Takayasu arteritis. European Journal of Internal Medicine, 2018, 50, 12-19.	2.2	30
42	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS ONE, 2018, 13, e0209343.	2.5	3
43	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. Frontiers in Immunology, 2018, 9, 809.	4.8	33
44	Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. Rheumatology, 2018, 57, ii51-ii62.	1.9	32
45	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. Autoimmunity Reviews, 2017, 16, 237-243.	5.8	25
46	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
47	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
48	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood, 2017, 130, 501-513.	1.4	90
49	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Annals of the Rheumatic Diseases, 2017, 76, 1624-1634.	0.9	67
50	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
51	The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2017, 2, 1018-1031.	0.8	21
52	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	27.0	974
53	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Seminars in Arthritis and Rheumatism, 2017, 46, 657-664.	3.4	62
54	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibodyâ€“associated vasculitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1684-1687.e10.	2.9	22

#	Article	IF	Citations
55	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virusâ€"Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2017, 15, 575-583.e1.	4.4	99
56	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open, 2017, 3, e000570.	3.8	33
57	Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 185-188.	0.8	0
58	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Medicine (United States), 2016, 95, e2368.	1.0	55
59	The Expanding Role of Imaging in Systemic Vasculitis. Rheumatic Disease Clinics of North America, 2016, 42, 733-751.	1.9	30
60	Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Science Signaling, 2016, 9, ra28.	3.6	44
61	Blocking interferon Î³ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1177-1186.	0.9	89
62	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. Autoimmunity Reviews, 2016, 15, 9-15.	5.8	62
63	Diagnostic clues for giant cell arteritis: Beyond headache and ischemic optic neuritis. Medicina ClÃnica (English Edition), 2015, 144, 380-381.	0.2	0
64	Urologic and male genital manifestations of granulomatosis with polyangiitis. Autoimmunity Reviews, 2015, 14, 897-902.	5.8	43
65	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2569-2580.	5.6	146
66	Imaging in systemic vasculitis. Current Opinion in Rheumatology, 2015, 27, 53-62.	4.3	49
67	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
68	Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. Medicine (United States), 2015, 94, e486.	1.0	78
69	Sustained Remission: An Unmet Need in Patients with Giant-cell Arteritis. Journal of Rheumatology, 2015, 42, 1081-1082.	2.0	2
70	Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. Journal of the American Geriatrics Society, 2015, 63, 415-416.	2.6	3
71	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.9	220
72	Advances in the Diagnosis of Large Vessel Vasculitis. Rheumatic Disease Clinics of North America, 2015, 41, 125-140.	1.9	15

#	Article	IF	Citations
73	Influence of theIL17A locusin giant cell arteritis susceptibility. Annals of the Rheumatic Diseases, 2014, 73, 1742-1745.	0.9	36
74	3. Pathogenesis of giant cell arteritis. Rheumatology, 2014, 53, i2-i3.	1.9	5
75	Authorsâ€™ response to the eLetter by Moiseevet al. Annals of the Rheumatic Diseases, 2014, 73, e71-e71.	0.9	0
76	Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Annals of the Rheumatic Diseases, 2014, 73, 1826-1832.	0.9	103
77	New insights into the molecular basis of systemic vasculitis. Nature Reviews Rheumatology, 2014, 10, 323-324.	8.0	0
78	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. Seminars in Arthritis and Rheumatism, 2014, 43, 772-777.	3.4	28
79	Diagnosis and classification of polyarteritis nodosa. Journal of Autoimmunity, 2014, 48-49, 84-89.	6.5	189
80	Scalp Necrosis in Giant Cell Arteritis. Mayo Clinic Proceedings, 2014, 89, e99.	3.0	1
81	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Annals of the Rheumatic Diseases, 2014, 73, 616-623.	0.9	68
82	Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, caseâ€“control study. Annals of the Rheumatic Diseases, 2014, 73, 1388-1392.	0.9	148
83	SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood, 2014, 124, 2235-2247.	1.4	94
84	Relapses in Patients With Giant Cell Arteritis. Medicine (United States), 2014, 93, 194-201.	1.0	158
85	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
86	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 2013, 65, 1-11.	6.7	4,839
87	Evidence of association of theNLRP1gene with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 628-630.	0.9	23
88	Early improvement of radiological signs of large-vessel inflammation in giant cell arteritis upon glucocorticoid treatment. Rheumatology, 2013, 52, 1335-1336.	1.9	9
89	Identification of thePTPN22functional variant R620W as susceptibility genetic factor for giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1882-1886.	0.9	51
90	Functionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et al. Arthritis and Rheumatism, 2013, 65, 1133-1134.	6.7	1

#	Article	IF	Citations
91	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1481-1487.	0.9	96
92	Life-Threatening Cryoglobulinemic Patients With Hepatitis C. Medicine (United States), 2013, 92, 273-284.	1.0	69
93	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2012, 71, 484-492.	0.9	451
94	B lymphocytes may play a significant role in large-vessel vasculitis. International Journal of Clinical Rheumatology, 2012, 7, 475-477.	0.3	2
95	The Search for Genetic Links in ANCA-Associated Vasculitis and Its Variants. New England Journal of Medicine, 2012, 367, 271-273.	27.0	4
96	Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology, 2012, 51, 841-851.	1.9	38
97	Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Annals of the Rheumatic Diseases, 2012, 71, 1170-1176.	0.9	300
98	The cryoglobulinaemias. Lancet, The, 2012, 379, 348-360.	13.7	460
99	Patient-reported Outcomes in Polymyalgia Rheumatica. Journal of Rheumatology, 2012, 39, 795-803.	2.0	64
100	Selective upâ€regulation of the soluble patternâ€recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. Arthritis and Rheumatism, 2012, 64, 854-865.	6.7	89
101	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
102	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
103	Type 1 autoimmune hepatitis in a patient with microscopic polyangiitis: challenges in diagnosis and treatment. Medicina ClÃnica, 2011, 136, 345-348.	0.6	0
104	Central Nervous System Vasculitis: Still More Questions than Answers. Current Neuropharmacology, 2011, 9, 437-448.	2.9	64
105	Treatment of Large Vessel Vasculitis. Current Immunology Reviews, 2011, 7, 435-442.	1.2	7
106	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology, 2011, 50, 2061-2070.	1.9	97
107	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor Î± and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Research, 2010, 62, 835-841.	3.4	75
108	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Annals of the Rheumatic Diseases, 2010, 69, 434-442.	0.9	59

#	Article	IF	Citations
109	Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica, 2010, 95, 456-463.	3.5	16
110	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
111	Treatment of Polymyalgia Rheumatica. Archives of Internal Medicine, 2009, 169, 1839.	3.8	104
112	Smallâ€vessel vasculitis surrounding an uninflamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: Comment on the article by Chatelain et al. Arthritis and Rheumatism, 2009, 60, 2853-2854.	6.7	2
113	The spectrum of vascular involvement in giantâ€cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. Apmis, 2009, 117, 10-20.	2.0	44
114	EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 310-317.	0.9	889
115	EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 318-323.	0.9	596
116	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A crossâ€sectional screening of fiftyâ€four prospectively followed patients. Arthritis and Rheumatism, 2008, 59, 422-430.	6.7	174
117	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	3.2	41
118	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Annals of the Rheumatic Diseases, 2008, 67, 1581-1588.	0.9	71
119	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
120	Systemic vasculitis: still a long and winding road. Current Opinion in Rheumatology, 2008, 20, 1-2.	4.3	2
121	How Is Infliximab Harmful?. Annals of Internal Medicine, 2008, 148, 166.	3.9	1
122	Gelatinase expression and proteolytic activity in giant-cell arteritis. Annals of the Rheumatic Diseases, 2007, 66, 1429-1435.	0.9	76
123	Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2938-2943.	3.6	141
124	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. Annals of Internal Medicine, 2007, 146, 621.	3.9	491
125	Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica. Medicine (United States), 2007, 86, 233-241.	1.0	38
126	Five Clinical Conundrums in the Management of Giant Cell Arteritis. Rheumatic Disease Clinics of North America, 2007, 33, 819-834.	1.9	26

#	Article	IF	Citations
127	Sustained spontaneous clinical remission in giant cell arteritis: Report of two cases with long-term followup. Arthritis and Rheumatism, 2006, 55, 160-162.	6.7	17
128	Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis*. Rheumatology, 2006, 45, 1356-1363.	1.9	64
129	Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. New England Journal of Medicine, 2006, 355, 1278-1280.	27.0	8
130	Dual function of focal adhesion kinase in regulating integrinâ€induced MMPâ€2 and MMPâ€9 release by human T lymphoid cells. FASEB Journal, 2005, 19, 1875-1877.	0.5	46
131	Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Current Rheumatology Reports, 2004, 6, 184-194.	4.7	43
132	Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. Journal of Pathology, 2004, 204, 311-316.	4.5	88
133	Antiangiogenic effects of anti-tumor necrosis factor Î± therapy with infliximab in psoriatic arthritis. Arthritis and Rheumatism, 2004, 50, 1636-1641.	6.7	137
134	Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis and Rheumatism, 2004, 51, 674-678.	6.7	48
135	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	3.2	34
136	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	3.5	100
137	Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 819-825.	6.7	35
138	Tissue production of pro-inflammatory cytokines (IL-1Â, TNFÂ and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. British Journal of Rheumatology, 2003, 43, 294-301.	2.3	237
139	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. Circulation, 2003, 107, 2428-2434.	1.6	169
140	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. Circulation, 2002, 106, 1664-1671.	1.6	99
141	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480
142	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis and Rheumatism, 2002, 47, 29-35.	6.7	127
143	Estrogens and the Vascular Endothelium. Annals of the New York Academy of Sciences, 2002, 966, 143-157.	3.8	120
144	Endothelial cell biology, perivascular inflammation, and vasculitis.. Cleveland Clinic Journal of Medicine, 2002, 69, SII45-SII45.	1.3	21

#	Article	IF	Citations
145	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. Arthritis and Rheumatism, 2001, 44, 1387-1395.	6.7	105
146	Tissue targeting and disease patterns in systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2001, 15, 259-279.	3.3	13
147	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis and Rheumatism, 2000, 43, 184-194.	6.7	128
148	Fibronectin Upregulates Gelatinase B (MMP-9) and Induces Coordinated Expression of Gelatinase A (MMP-2) and Its Activator MT1-MMP (MMP-14) by Human T Lymphocyte Cell Lines. A Process Repressed Through RAS/MAP Kinase Signaling Pathways. Blood, 1999, 94, 2754-2766.	1.4	177
149	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. Journal of Infectious Diseases, 1999, 179, 475-483.	4.0	23
150	Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis, 1999, 3, 271-280.	7.2	34
151	Interferon-? may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. Arthritis and Rheumatism, 1999, 42, 1051-1055.	6.7	68
152	Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis and Rheumatism, 1998, 41, 26-32.	6.7	255
153	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis and Rheumatism, 1998, 41, 435-444.	6.7	56
154	Preparation of Endothelial Cells. Current Protocols in Cell Biology, 1998, 00, Unit 2.3.	2.3	4
155	Large vessel vasculitides. Current Opinion in Rheumatology, 1998, 10, 18-28.	4.3	78
156	T-cell population of primary and secondary cutaneous B-cell lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA). Archives of Dermatological Research, 1997, 289, 327-330.	1.9	5
157	New developments in the pathogenesis of systemic vasculitis. Current Opinion in Rheumatology, 1996, 8, 1-11.	4.3	51
158	OESTROGEN AND ENDOTHELIAL CELL ANGIOGENIC ACTIVITY. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 247-250.	1.9	36
159	Expression of an Estrogen Receptor by Human Coronary Artery and Umbilical Vein Endothelial Cells. Circulation, 1996, 94, 1402-1407.	1.6	172
160	Membrane Attack Complex Deposits in Cutaneous Lesions of Dermatomyositis. Archives of Dermatology, 1995, 131, 1386.	1.4	55
161	Estrogen Promotes Angiogenic Activity in Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model. Circulation, 1995, 91, 755-763.	1.6	382
162	Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in Î²1 and Î²2 integrin function. European Journal of Immunology, 1994, 24, 1377-1382.	2.9	50

#	Article	IF	Citations
163	Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis and Rheumatism, 1994, 37, 1055-1061.	6.7	67
164	Malignant histiocytosis as a fatal complication of systemic lupus erythematosus. Arthritis and Rheumatism, 1991, 34, 1557-1559.	6.7	1
165	Giant-Cell Arteritis Presenting with Ipsilateral Hemiplegia and Lateral Medullary Syndrome. European Neurology, 1989, 29, 266-268.	1.4	23
166	Recurrent Arterial Thrombosis in a Patient with Giant-cell Arteritis and Raised Anticardiolipin Antibody Levels. Rheumatology, 1988, 27, 164-165.	1.9	21